Orbimed Advisors LLC Cytom X Therapeutics, Inc. Transaction History
Orbimed Advisors LLC
- $2.8 Billion
- Q2 2025
A detailed history of Orbimed Advisors LLC transactions in Cytom X Therapeutics, Inc. stock. As of the latest transaction made, Orbimed Advisors LLC holds 8,461,500 shares of CTMX stock, worth $15.7 Million. This represents 0.69% of its overall portfolio holdings.
Number of Shares
8,461,500Holding current value
$15.7 Million% of portfolio
0.69%Shares
6 transactions
Others Institutions Holding CTMX
# of Institutions
84Shares Held
121MCall Options Held
243KPut Options Held
121K-
Vr Adviser, LLC New York, NY14MShares$26 Million6.28% of portfolio
-
Tang Capital Management LLC San Diego, CA11.1MShares$20.6 Million1.5% of portfolio
-
Vanguard Group Inc Valley Forge, PA9.38MShares$17.4 Million0.0% of portfolio
-
Steven Cohen Point72 Asset Management, L.P. | Stamford, Ct8.08MShares$15 Million0.04% of portfolio
-
Commodore Capital LP New York, NY7.69MShares$14.3 Million1.63% of portfolio
About CytomX Therapeutics, Inc.
- Ticker CTMX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 65,950,200
- Market Cap $123M
- Description
- CytomX Therapeutics, Inc. operates as an oncology-focused biopharmaceutical company in the United States. The company develops antibody therapeutics based on its Probody technology platform for the treatment of cancer. The company's product candidates include CX-2009, an antibody drug conjugates (ADC) against CD166, which is in Phase II clinical...